1. Scrip

Pierre Fabre Launches Pivotal Trial Of Pioneering Prenatal Therapy

XLHED Drug Finally Makes It To The Clinic

 
• By Kevin Grogan

The first boy suffering from X-linked hypohidrotic ectodermal dysplasia has been injected with a protein replacement therapy developed by the French firm and the Esperare Foundation while inside his mother's womb.

Newborn baby boy lying on bed, sleeping, close up
XLHED affects four out of 100,000 live male births every year • Source: Archive

Pierre Fabre is hoping that it can succeed where a host of companies have failed in getting a treatment onto the market for X-linked hypohidrotic ectodermal dysplasia (XLHED), a rare pediatric genetic disease.

The French firm and the Switzerland-based EspeRare Foundation announced that the first patient in the Phase II pivotal EDELIFE clinical trial has received the three rounds of ER004

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.